{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:10:12Z","timestamp":1790435412882,"version":"4.1.0"},"reference-count":119,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2016,12,15]]},"DOI":"10.3233\/jhd-160200","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T00:30:00Z","timestamp":1481934600000},"page":"333-342","source":"Crossref","is-referenced-by-count":29,"title":["Targeting the Cholinergic System to Develop a Novel Therapy for Huntington\u2019s Disease"],"prefix":"10.1177","volume":"5","author":[{"given":"Gary X.","family":"D\u2019Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Waldvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"9557","key":"10.3233\/JHD-160200_ref1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"issue":"4-5","key":"10.3233\/JHD-160200_ref2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.brainresbull.2009.07.010","article-title":"Role of mitochondrial dysfunction in the pathogenesis of Huntington\u2019s disease","volume":"80","author":"Quintanilla","year":"2009","journal-title":"Brain Res Bull"},{"issue":"3","key":"10.3233\/JHD-160200_ref3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.arcmed.2007.11.011","article-title":"Excitotoxic neuronal death and the pathogenesis of Huntington\u2019s disease","volume":"39","author":"Estrada-S\u00e1nchez","year":"2008","journal-title":"Arch Med Res"},{"issue":"6","key":"10.3233\/JHD-160200_ref4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/107385840100700604","article-title":"Caspases in Huntington\u2019s disease","volume":"7","author":"Sanchez-Mejia","year":"2001","journal-title":"Neuroscientist"},{"issue":"4","key":"10.3233\/JHD-160200_ref5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0300-9084(02)01398-6","article-title":"Protein aggregation in Huntington\u2019s disease","volume":"84","author":"Hoffner","year":"2002","journal-title":"Biochimie"},{"issue":"9","key":"10.3233\/JHD-160200_ref6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington\u2019s disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci"},{"issue":"17","key":"10.3233\/JHD-160200_ref7","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00018-005-5084-5","article-title":"Synaptic dysfunction in Huntington\u2019s disease: A new perspective","volume":"62","author":"Smith","year":"2005","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.3233\/JHD-160200_ref8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2014.09.003","article-title":"Autophagy in Huntington disease and huntingtin in autophagy","volume":"38","author":"Martin","year":"2015","journal-title":"Trends Neurosci"},{"issue":"3","key":"10.3233\/JHD-160200_ref9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/jpet.102.041616","article-title":"The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: Recent challenges and their implications for novel drug development","volume":"306","author":"Terry","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"4558","key":"10.3233\/JHD-160200_ref10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"issue":"2","key":"10.3233\/JHD-160200_ref11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0031-6997(25)07156-X","article-title":"Behavioral and electroencephalographic effects of atropine and related compounds","volume":"18","author":"Longo","year":"1966","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.3233\/JHD-160200_ref12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","article-title":"Human memory and the cholinergic system. A relationship to aging?","volume":"30","author":"Drachman","year":"1974","journal-title":"Arch Neurol"},{"issue":"1","key":"10.3233\/JHD-160200_ref13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0091-3057(76)90286-0","article-title":"Short-term memory in the rhesus monkey: Disruption from the anti-cholinergic scopolamine","volume":"5","author":"Bartus","year":"1976","journal-title":"Pharmacol Biochem Behav"},{"issue":"4537","key":"10.3233\/JHD-160200_ref14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer\u2019s disease and senile dementia: Loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"issue":"11","key":"10.3233\/JHD-160200_ref15","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1523\/JNEUROSCI.03-11-02286.1983","article-title":"Identification of central cholinergic neurons containing both choline acetyltransferase and acetylcholinesterase and of central neurons containing only acetylcholinesterase","volume":"3","author":"Eckenstein","year":"1983","journal-title":"J Neurosci"},{"issue":"2","key":"10.3233\/JHD-160200_ref16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","article-title":"Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue","volume":"34","author":"Perry","year":"1977","journal-title":"J Neurol Sci"},{"issue":"3-4","key":"10.3233\/JHD-160200_ref17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF01243353","article-title":"Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level","volume":"67","author":"Nilsson","year":"1986","journal-title":"J Neural Transm"},{"issue":"1-2","key":"10.3233\/JHD-160200_ref18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0006-8993(83)90017-3","article-title":"Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer\u2019s disease","volume":"289","author":"Rylett","year":"1983","journal-title":"Brain Res"},{"issue":"3","key":"10.3233\/JHD-160200_ref19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/brain\/99.3.459","article-title":"Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies","volume":"99","author":"Bowen","year":"1976","journal-title":"Brain"},{"issue":"8000","key":"10.3233\/JHD-160200_ref20","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer\u2019s disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"issue":"5","key":"10.3233\/JHD-160200_ref21","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1152\/jn.2000.83.5.2649","article-title":"Electrophysiological properties of cholinergic and noncholinergic neurons in the ventral pallidal region of the nucleus basalis in rat brain slices","volume":"83","author":"Bengtson","year":"2000","journal-title":"J Neurophysiol"},{"issue":"21","key":"10.3233\/JHD-160200_ref22","first-page":"1","article-title":"Adult mouse basal forebrain harbors two distinct cholinergic populations defined by their electrophysiology","volume":"6","author":"Unal","year":"2012","journal-title":"Front Behav Neurosci"},{"key":"10.3233\/JHD-160200_ref23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/npp.2010.104","article-title":"Modes and models of forebrain cholinergic neuromodulation of cognition","volume":"36","author":"Hasselmo","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.3233\/JHD-160200_ref24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuron.2007.08.025","article-title":"Prefrontal acetylcholine release controls cue detection on multiple timescales","volume":"56","author":"Parikh","year":"2007","journal-title":"Neuron"},{"key":"10.3233\/JHD-160200_ref25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1196\/annals.1417.021","article-title":"Cholinergic mediation of attention: Contributions of phasic and tonic increases in prefrontal cholinergic activity","volume":"1129","author":"Parikh","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JHD-160200_ref26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.1991.tb03105.x","article-title":"The basal forebrain cholinergic system: Efferent and afferent connectivity and long-term effects of lesions","volume":"366","author":"Gaykema","year":"1991","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"10.3233\/JHD-160200_ref27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/0306-4522(83)90108-2","article-title":"Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1\u2013Ch6)","volume":"10","author":"Mesulam","year":"1983","journal-title":"Neuroscience"},{"issue":"3","key":"10.3233\/JHD-160200_ref28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1139\/y86-059","article-title":"Possible destruction of cholinoceptive neurons by overstimulation of cholinergic tracts","volume":"64","author":"McGeer","year":"1986","journal-title":"Can J Physiol Pharmacol"},{"issue":"3","key":"10.3233\/JHD-160200_ref29","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/0306-4522(87)90176-X","article-title":"Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: Neuroanatomical and electrophysiological evidence","volume":"23","author":"Clarke","year":"1987","journal-title":"Neuroscience"},{"key":"10.3233\/JHD-160200_ref30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-374767-9.00007-X","volume-title":"Handbook of Basal Ganglia Structure and Function","author":"Goldberg","year":"2010"},{"issue":"5","key":"10.3233\/JHD-160200_ref31","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1523\/JNEUROSCI.4082-10.2011","article-title":"The distinct role of medium spiny neurons and cholinergic interneurons in the D2\/A2A receptor interaction in the striatum: Implications for Parkinson\u2019s disease","volume":"31","author":"Tozzi","year":"2011","journal-title":"J Neurosci"},{"issue":"8","key":"10.3233\/JHD-160200_ref32","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/nn.3743","article-title":"Direct and indirect pathways of basal ganglia: A critical reappraisal","volume":"17","author":"Calabresi","year":"2014","journal-title":"Nat Neurosci"},{"issue":"17","key":"10.3233\/JHD-160200_ref33","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1002\/cne.24013","article-title":"Cholinergic interneurons in the Q140 knockin mouse model of Huntington\u2019s disease: Reductions in dendritic branching and thalamostriatal input","volume":"524","author":"Deng","year":"2016","journal-title":"J Comp Neurol"},{"issue":"4","key":"10.3233\/JHD-160200_ref34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/syn.1089","article-title":"Vesicular neurotransmitter transporters in Huntington\u2019s disease: Initial observations and comparison with traditional synaptic markers","volume":"41","author":"Suzuki","year":"2001","journal-title":"Synapse"},{"issue":"7","key":"10.3233\/JHD-160200_ref35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0024-3205(76)90295-2","article-title":"Huntington\u2019s disease: Regional alteration in muscarinic cholinergic receptor binding in human brain","volume":"19","author":"Wastek","year":"1976","journal-title":"Life Sci"},{"issue":"1","key":"10.3233\/JHD-160200_ref36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/brain\/103.1.179","article-title":"Neurochemical alterations in Huntington\u2019s chorea: A study of post-mortem brain tissue","volume":"103","author":"Spokes","year":"1980","journal-title":"Brain"},{"issue":"2","key":"10.3233\/JHD-160200_ref37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00862983","article-title":"Brain muscarinic cholinergic receptors in Huntington\u2019s disease","volume":"239","author":"Lange","year":"1992","journal-title":"J Neurol"},{"issue":"2","key":"10.3233\/JHD-160200_ref38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0022-510X(85)90112-1","article-title":"Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington\u2019s disease and agonal cases","volume":"67","author":"Butterworth","year":"1985","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.3233\/JHD-160200_ref39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ana.410130116","article-title":"Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain","volume":"13","author":"Sorbi","year":"1983","journal-title":"Ann Neurol"},{"issue":"5","key":"10.3233\/JHD-160200_ref40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00314742","article-title":"Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington\u2019s disease","volume":"237","author":"Manyam","year":"1990","journal-title":"J Neurol"},{"issue":"21","key":"10.3233\/JHD-160200_ref41","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1093\/hmg\/ddl252","article-title":"Cholinergic neuronal defect without cell loss in Huntington\u2019s disease","volume":"15","author":"Smith","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.3233\/JHD-160200_ref42","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1046\/j.1471-4159.2003.01704.x","article-title":"Mice transgenic for exon 1 of Huntington\u2019s disease: Properties of cholinergic and dopaminergic pre-synaptic function in the striatum","volume":"85","author":"Vetter","year":"2003","journal-title":"J Neurochem"},{"issue":"2","key":"10.3233\/JHD-160200_ref43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.expneurol.2011.08.010","article-title":"Reduced striatal acetylcholine efflux in the R6\/2 mouse model of Huntington\u2019s disease: An examination of the role of altered inhibitory and excitatory mechanisms","volume":"232","author":"Farrar","year":"2011","journal-title":"Exp Neurol"},{"key":"10.3233\/JHD-160200_ref44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/7854_2014_354","article-title":"The neuropathology of Huntington\u2019s disease","volume":"22","author":"Waldvogel","year":"2015","journal-title":"Curr Top Behav Neurosci"},{"key":"10.3233\/JHD-160200_ref45","first-page":"1","article-title":"Enhanced GABAergic inputs contribute to functional alterations of cholinergic interneurons in the R6\/2 mouse model of Huntington\u2019s disease","volume":"e0008","author":"Holley","year":"2015","journal-title":"eNeuro"},{"issue":"1","key":"10.3233\/JHD-160200_ref46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0006-8993(87)90694-9","article-title":"Sparing of acetylcholinesterase-containing striatal neurons in Huntington\u2019s disease","volume":"411","author":"Ferrante","year":"1987","journal-title":"Brain Res"},{"issue":"10","key":"10.3233\/JHD-160200_ref47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tins.2007.07.008","article-title":"Re-emergence of striatal cholinergic interneurons in movement disorders","volume":"30","author":"Pisani","year":"2007","journal-title":"Trends Neurosci"},{"issue":"1","key":"10.3233\/JHD-160200_ref48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3233\/JHD-120026","article-title":"NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington\u2019s disease","volume":"2","author":"Zhang","year":"2013","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-160200_ref49","doi-asserted-by":"crossref","unstructured":"Pawlik K , Rosenzweig MR . editors. The International Handbook of Psychology. London SAGE Publications Ltd; 2000.","DOI":"10.4135\/9781848608399"},{"issue":"3","key":"10.3233\/JHD-160200_ref50","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.nbd.2007.11.006","article-title":"Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington\u2019s disease transgenic mice","volume":"29","author":"Nithianantharajah","year":"2008","journal-title":"Neurobiol Dis"},{"issue":"5529","key":"10.3233\/JHD-160200_ref51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease","volume":"293","author":"Zuccato","year":"2010","journal-title":"Science"},{"key":"10.3233\/JHD-160200_ref52","doi-asserted-by":"crossref","unstructured":"Jenden DD , editor. Cholinergic Mechanisms and Psychopharmacology. New York: Plenum Press; 1978.","DOI":"10.1007\/978-1-4684-3096-7"},{"issue":"1","key":"10.3233\/JHD-160200_ref53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/exnr.1999.7168","article-title":"The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington\u2019s disease","volume":"159","author":"Alexi","year":"1999","journal-title":"Exp Neurol"},{"key":"10.3233\/JHD-160200_ref54","first-page":"175","article-title":"Nicotinic and muscarinic cholinergic receptors in Alzheimer\u2019s disease and related disorders","volume":"24","author":"Whitehouse","year":"1987","journal-title":"J Neural Transm Suppl"},{"issue":"6","key":"10.3233\/JHD-160200_ref55","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/jnnp.50.6.806","article-title":"Nicotinic receptor abnormalities in Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"50","author":"Perry","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.3233\/JHD-160200_ref56","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1-2","key":"10.3233\/JHD-160200_ref57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2011.12.014","article-title":"NGF and nitrosative stress in patients with Huntington\u2019s disease","volume":"315","author":"Tasset","year":"2012","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.3233\/JHD-160200_ref58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.6646","article-title":"p75NTR in Huntington\u2019s disease: Beyond the basal ganglia","volume":"7","author":"Brito","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.3233\/JHD-160200_ref59","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1172\/JCI74809","article-title":"Neurotrophin receptor p75(NTR) mediates Huntington\u2019s disease-associated synaptic and memory dysfunction","volume":"124","author":"Brito","year":"2014","journal-title":"J Clin Invest"},{"issue":"15","key":"10.3233\/JHD-160200_ref60","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.281.15.1401","article-title":"Cholinergic markers in elderly patients with early signs of Alzheimer disease","volume":"281","author":"Davis","year":"1999","journal-title":"JAMA"},{"issue":"9","key":"10.3233\/JHD-160200_ref61","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1212\/WNL.27.9.887","article-title":"Choline therapy in Huntington chorea","volume":"27","author":"Aquilonius","year":"1997","journal-title":"Neurology"},{"key":"10.3233\/JHD-160200_ref62","first-page":"765","article-title":"Oral choline administration to patients with Huntington\u2019s disease","volume":"23","author":"Growdon","year":"1979","journal-title":"Adv Neurol"},{"issue":"12","key":"10.3233\/JHD-160200_ref63","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington\u2019s disease","volume":"19","author":"De Tommaso","year":"2004","journal-title":"Mov Disord"},{"issue":"1","key":"10.3233\/JHD-160200_ref64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","article-title":"Two years\u2019 follow-up of rivastigmine treatment in Huntington disease","volume":"30","author":"De Tommasso","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.3233\/JHD-160200_ref65","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","article-title":"Rivastigmine in the treatment of Huntington\u2019s disease","volume":"9","author":"Rot","year":"2002","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.3233\/JHD-160200_ref66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.46867\/ijcp.2014.27.03.08","article-title":"Cognitive deficits in the R6\/2 mouse model of Huntington\u2019s disease and their amelioration with Donepezil","volume":"27","author":"Murphy","year":"2014","journal-title":"Int J Comp Psychol"},{"issue":"1","key":"10.3233\/JHD-160200_ref67","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","article-title":"Donepezil for Huntington\u2019s disease","volume":"15","author":"Fernandez","year":"2000","journal-title":"Mov Disorders"},{"issue":"7","key":"10.3233\/JHD-160200_ref68","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-160200_ref69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neulet.2008.10.020","article-title":"Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington\u2019s disease","volume":"448","author":"Park","year":"2008","journal-title":"Neuroscience Lett"},{"issue":"1","key":"10.3233\/JHD-160200_ref70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200401000-00010","article-title":"Treatment of Huntington\u2019s disease with galantamine","volume":"19","author":"Petrikis","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"issue":"8","key":"10.3233\/JHD-160200_ref71","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-010-0430-7","article-title":"Neuroinflammation in Huntington\u2019s disease","volume":"117","author":"Moller","year":"2010","journal-title":"J Neural Transm"},{"issue":"6","key":"10.3233\/JHD-160200_ref72","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","article-title":"The choreography of neuroinflammation in Huntington\u2019s disease","volume":"36","author":"Crotti","year":"2015","journal-title":"Trends Immunol"},{"issue":"1","key":"10.3233\/JHD-160200_ref73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1753425909104680","article-title":"Inhibitory role of cholinergic system mediated via alpha7 nicotinic acetylcholine receptor in LPS-induced neuroinflammation","volume":"16","author":"Tyagi","year":"2010","journal-title":"Innate Immun"},{"issue":"4","key":"10.3233\/JHD-160200_ref74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/jnc.12817","article-title":"Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture","volume":"131","author":"Han","year":"2014","journal-title":"J Neurochem"},{"issue":"98","key":"10.3233\/JHD-160200_ref75","first-page":"1","article-title":"\u03b17 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation","volume":"9","author":"Liu","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.3233\/JHD-160200_ref76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2008.06.018","article-title":"Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine","volume":"203","author":"Nizri","year":"2008","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.3233\/JHD-160200_ref77","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0024-3205(71)90146-9","article-title":"Cholinergic and dopaminergic mechanisms in Huntington\u2019s chorea","volume":"10","author":"Aquilonius","year":"1971","journal-title":"Life Sci"},{"issue":"5","key":"10.3233\/JHD-160200_ref78","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000102851","article-title":"Physostigmine in rigid Huntington\u2019s disease","volume":"35","author":"Fann","year":"1973","journal-title":"Confin Neurol"},{"issue":"6","key":"10.3233\/JHD-160200_ref79","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.neuropharm.2009.12.005","article-title":"Agonist-induced restoration of hippocampal neurogenesis and cognitive improvement in a model of cholinergic denervation","volume":"58","author":"Van Kampen","year":"2010","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.3233\/JHD-160200_ref80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1212\/WNL.33.7.932","article-title":"Effect of cholinergic agents in Huntington\u2019s disease: A reappraisal","volume":"33","author":"Nutt","year":"1983","journal-title":"Neurology"},{"issue":"5","key":"10.3233\/JHD-160200_ref81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington\u2019s disease: An open label study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.3233\/JHD-160200_ref82","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"issue":"4","key":"10.3233\/JHD-160200_ref83","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0004-282X2004000600030","article-title":"Functional and motor response to low dose olanzapine in Huntington\u2019s disease: Case report","volume":"62","author":"Laks","year":"2004","journal-title":"Arq Neuropsiquiatr"},{"issue":"13","key":"10.3233\/JHD-160200_ref84","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington\u2019s disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N Engl J Med"},{"issue":"45","key":"10.3233\/JHD-160200_ref85","doi-asserted-by":"crossref","first-page":"14078","DOI":"10.1073\/pnas.1512812112","article-title":"Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice","volume":"112","author":"Pancani","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.3233\/JHD-160200_ref86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nbd.2005.10.009","article-title":"Plastic and behavioral abnormalities in experimental Huntington\u2019s disease: A crucial role for cholinergic interneurons","volume":"22","author":"Picconi","year":"2006","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.3233\/JHD-160200_ref87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbr.2010.05.023","article-title":"Genetically engineered mesenchymal stem cells reduce behavioural deficits in the YAC128 mouse model of Huntington\u2019s disease","volume":"214","author":"Dey","year":"2010","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.3233\/JHD-160200_ref88","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0896-6273(95)90051-9","article-title":"Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrain","volume":"15","author":"Martinez-Serrano","year":"1995","journal-title":"Neuron"},{"issue":"2-3","key":"10.3233\/JHD-160200_ref89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3940(01)02098-5","article-title":"Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes","volume":"310","author":"Mizuta","year":"2001","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.3233\/JHD-160200_ref90","first-page":"217","article-title":"Nerve growth factor and striatal glutathione metabolism in a rat model of Huntington\u2019s disease","volume":"17","author":"Cruz-Aquado","year":"2000","journal-title":"Restor Neurol Neurosci"},{"issue":"1","key":"10.3233\/JHD-160200_ref91","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1999.7253","article-title":"Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage","volume":"161","author":"Menei","year":"2000","journal-title":"Exp Neurol"},{"issue":"5","key":"10.3233\/JHD-160200_ref92","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1460-9568.1994.tb00982.x","article-title":"Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in rat neostriatum","volume":"6","author":"Perez-Navarro","year":"1994","journal-title":"Eur J Neurosci"},{"issue":"2","key":"10.3233\/JHD-160200_ref93","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3940(92)90092-L","article-title":"Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones","volume":"140","author":"Davies","year":"1992","journal-title":"Neurosci Lett"},{"key":"10.3233\/JHD-160200_ref94","first-page":"195","article-title":"Neurotrophic factors in Huntington\u2019s disease","volume":"146","author":"Alberch","year":"2004","journal-title":"Prog Brain Res"},{"issue":"2","key":"10.3233\/JHD-160200_ref95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0306-4522(94)90229-1","article-title":"Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA","volume":"61","author":"Venero","year":"1994","journal-title":"Neuroscience"},{"issue":"8","key":"10.3233\/JHD-160200_ref96","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/mds.26300","article-title":"Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease","volume":"30","author":"Deffains","year":"2015","journal-title":"Mov Disorders"},{"issue":"13","key":"10.3233\/JHD-160200_ref97","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum Mol Gen"},{"key":"10.3233\/JHD-160200_ref98","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainresbull.2006.10.018","article-title":"Selective degeneration in YAC mouse models of Huntington disease","volume":"72","author":"Van Raamsdonk","year":"2007","journal-title":"Brain Res Bull"},{"issue":"5093","key":"10.3233\/JHD-160200_ref99","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.8420006","article-title":"Blood-brain barrier penetration and in vivo activity of an NGF conjugate","volume":"259","author":"Friden","year":"1993","journal-title":"Science"},{"key":"10.3233\/JHD-160200_ref100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.expneurol.2016.05.002","article-title":"FoxP1 marks medium spiny neurons from precursors to maturity and is required for their differentiation","volume":"282","author":"Precious","year":"2016","journal-title":"Exp Neurol"},{"issue":"1","key":"10.3233\/JHD-160200_ref101","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuroscience.2006.12.064","article-title":"Determination of key aspects of precursor cell proliferation, cell cycle length and kinetics in the adult mouse subgranular zone","volume":"146","author":"Mandyam","year":"2008","journal-title":"Neuroscience"},{"issue":"22","key":"10.3233\/JHD-160200_ref102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399403006549","article-title":"Huntington\u2019s disease: Molecular basis of neurodegeneration","volume":"5","author":"Rubinsztein","year":"2003","journal-title":"Expert Rev Mol Med"},{"issue":"4","key":"10.3233\/JHD-160200_ref103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/mds.870130405","article-title":"Effects of SIB-Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys","volume":"13","author":"Schneider","year":"1998","journal-title":"Mov Disorders"},{"key":"10.3233\/JHD-160200_ref104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2013.01.001","article-title":"New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer\u2019s disease","volume":"537","author":"Nie","year":"2013","journal-title":"Neurosci Lett"},{"issue":"21","key":"10.3233\/JHD-160200_ref105","doi-asserted-by":"crossref","first-page":"9181","DOI":"10.1021\/jm3006542","article-title":"Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-AZDa novel highly selective \u03b14\u03b22 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders","volume":"55","author":"Mazurov","year":"2012","journal-title":"J Med Chem"},{"issue":"3","key":"10.3233\/JHD-160200_ref106","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002130000531","article-title":"Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-Y, in the learned helplessness rat model of depression","volume":"152","author":"Ferguson","year":"2000","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.3233\/JHD-160200_ref107","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.neuropharm.2007.01.006","article-title":"Cytisine, a partial agonist of high affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL\/6J mice","volume":"52","author":"Mineur","year":"2007","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.3233\/JHD-160200_ref108","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1527-3458.2004.tb00010.x","article-title":"TC-An orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects","volume":"10","author":"Gatto","year":"2004","journal-title":"CNS Drug Rev"},{"issue":"2","key":"10.3233\/JHD-160200_ref109","first-page":"57","article-title":"Involvement of alpha7 nAChR downregulation in rat oxaliplatin-induced neuropathy","volume":"117","author":"Mannelli","year":"2012","journal-title":"Ital J Anat Embryol"},{"issue":"2","key":"10.3233\/JHD-160200_ref110","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","article-title":"EVP-6124, a novel and selective \u03b17 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of \u03b17 nicotinic acetylcholine receptors","volume":"62","author":"Prickaerts","year":"2012","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.3233\/JHD-160200_ref111","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.bcp.2009.05.030","article-title":"TC-An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia","volume":"78","author":"Hauser","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.3233\/JHD-160200_ref112","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/ntr\/ntt208","article-title":"Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control","volume":"16","author":"Rollema","year":"2014","journal-title":"Nicotine Tob Res"},{"key":"10.3233\/JHD-160200_ref113","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at \u03b14\u03b22 and a full agonist at \u03b17 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.3233\/JHD-160200_ref114","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/syn.20564","article-title":"Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats","volume":"62","author":"Zaniewska","year":"2008","journal-title":"Synapse"},{"key":"10.3233\/JHD-160200_ref115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.nlm.2008.03.002","article-title":"Varenicline ameliorates ethanol-induced deficits in learning in C57BL\/6 mice","volume":"90","author":"Gulick","year":"2008","journal-title":"Neurobiol Learn Mem"},{"issue":"5","key":"10.3233\/JHD-160200_ref116","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1037\/a0012601","article-title":"Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL\/6 mice","volume":"122","author":"Raybuck","year":"2008","journal-title":"Behav Neurosci"},{"key":"10.3233\/JHD-160200_ref117","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbr.2011.04.012","article-title":"A comparison of brain and behavioral effects of varenicline and nicotine in rats","volume":"223","author":"King","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.3233\/JHD-160200_ref118","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2009.01.002","article-title":"Varenicline has antidepressant-like activity in the forced swim test and augments sertraline\u2019s effect","volume":"605","author":"Rollema","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.3233\/JHD-160200_ref119","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.110.166280","article-title":"Nicotinic partial agonists Varenicline and Sazetidine-A have differential effects on affective behavior","volume":"334","author":"Turner","year":"2010","journal-title":"J Pharm Exp Ther"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-160200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:12Z","timestamp":1777453032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-160200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":119,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jhd-160200","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}